Ticker: BSPM, Company: Biostar Pharmaceuticals, Inc., Type: 8-K, Date: 2014-03-10
Original SEC Filing: Click here

---

Webplus: BSPM/20140310/8-K/2_EX-1.1/000.htm SEC Original: ex1-1.htm
CONFIDENTIAL March 1, 2014 MOODY CAPITAL SOLUTIONS, INC. 208 Summitrail Lane Dawsonville, GA 30524 Phone (770) 815-0885 Mr. Ronghua Wang Chairman and CEO Biostar Pharmaceuticals, Inc No. 588 Shiji Xi Avenue Xianyang, 712046 Phone: 86 29 3368 6638 Dear Mr. Wang: “ Moody Capital Solutions, Inc. Axiom Capital Management, Inc Biostar Pharmaceuticals, Inc. This letter (the The terms of such

---

---

Webplus: BSPM/20140310/8-K/3_EX-4.1/000.htm SEC Original: ex4-1.htm
BIOSTAR PHARMACEUTICALS, INC. Issuance Date Date of Issuance: March [___], 2014 (“ Company Holder 1 16 Securities Purchase Agreement Biostar Pharmaceuticals, Inc., a Maryland corporation (the “ 1. (a) Mechanics of Exercise 1 (f) Exercise Notice Aggregate Exercise Price 1 (d) st . Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1

---

---

Webplus: BSPM/20140310/8-K/4_EX-5.1/000.htm SEC Original: ex5-1.htm
March 10, 2014 Board of Directors Biostar Pharmaceuticals, Inc. No. 588 Shiji Avenue Xiangyang City, Shaanxi Province People’s Republic of China 712046 Company Shares Shares Shares Securities Purchase Agreement Registration Statement Commission Act Base Prospectus Prospectus Supplement Prospectus Schiff Hardin LLP EX-5.1 4 ex5-1.htm EX-5.1

---

---

Webplus: BSPM/20140310/8-K/5_EX-10.1/000.htm SEC Original: ex10-1.htm
SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT Agreement Company Buyer Buyers This RECITALS Registration Statement 1933 Act SEC Common Shares Common Stock B. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms stated in this Agreement, (i) the aggregate number of shares of Common Stock (as defined below) set forth opposite such Buyer’s name in column

---

---

Webplus: BSPM/20140310/8-K/6_EX-99.1/000.htm SEC Original: ex99-1.htm
Gross proceeds of the offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, are expected to be approximately $4.1 million. The net proceeds from this offering will be used for working capital and other general corporate purposes. The completion of the offering will occur on or before March 13, 2014. Moody Capital Solutions, Inc.

---

---

Webplus: BSPM/20140310/8-K/1/000.htm SEC Original: biostar8k030814.htm
FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): March 10, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨

---

Company Information:

Ticker: BSPM, Company: Biostar Pharmaceuticals, Inc., Type: 8-K, Date: 2014-03-10CIK: 0001418133, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
NO. 588 SHIJI XI AVENUE
XIANYANG, SHAANXI PROVINCE 712046